Physician profile
Monte B Pellmar
NPI 1700940954
$429,486.57
in general payments reported to CMS, 2019-2025
54 companies · $72K in 2025
The $72K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $54K · 2021: $72K · 2022: $54K · 2023: $38K · 2024: $58K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Honoraria: $34K · Food and Beverage: $11K · Consulting Fee: $9,713 · Travel and Lodging: $7,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,365.00 |
| Honoraria | $33,964.00 |
| Food and Beverage | $10,542.88 |
| Consulting Fee | $9,713.08 |
| Travel and Lodging | $7,065.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119,102.38 | 2021-2025 | |
| Amgen INC. | $79,587.98 | 2019-2024 | Aimovig |
| Allergan, INC. | $59,074.40 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $48,792.79 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Lundbeck LLC | $39,372.32 | 2020-2025 | Vyepti |
| Pfizer INC. | $29,115.36 | 2023-2025 | |
| Axsome Therapeutics, INC. | $19,768.55 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $15,643.23 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $8,771.85 | 2022 | |
| Promius Pharma LLC | $3,139.95 | 2019 | |
| Scilex Pharmaceuticals INC. | $2,221.70 | 2019-2024 | Ztlido, Elyxyb |
| Supernus Pharmaceuticals, INC. | $573.17 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $462.52 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $415.36 | 2022-2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $398.97 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Pellmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.